セッション詳細
[S-23]シンポジウム23 Alzheimer's disease and related dementias: diagnosis and therapies based on pathophysiology
2025年5月22日(木) 15:10 〜 17:10
第07会場(大阪国際会議場12F 特別会議場)
座長：岩坪 威（国立精神・神経医療研究センター神経研究所）, 井原 涼子（東京都健康長寿医療センター 脳神経内科）
As our understanding of the pathophysiology of Alzheimer's disease and related dementias has advanced, the application of biomarker-based early diagnosis, genetic risk estimation, and treatment based on disease mechanisms (disease-modifying therapies) are rapidly advancing. In this session, expert neurologists in Alzheimer's disease and related genetic dementing disorders from Japan and worldwide will discuss the frontiers of pathophysiology-based diagnosis and treatment.
[S-23-1]本邦におけるアルツハイマー病疾患修飾薬の実臨床への実装
井原 涼子 (東京都健康長寿医療センター 脳神経内科)
Dr. Ihara graduated from the University of Tokyo in 2002 and completed her neurology residency in 2007. She established memory clinics at the University of Tokyo Hospital in 2008. During her PhD, she conducted research on TDP-43 proteinopathy using a Drosophila model. After earning her PhD, she focused on clinical research and practice in Alzheimer’s disease. From 2015 to 2016, she joined the Knight ADRC at Washington University in St. Louis and contributed to the initiation of DIAN-Japan. Her main research interests include optimizing to identify individuals with preclinical Alzheimer’s disease and raising awareness of its earliest stages. Currently, she is leading efforts to integrate anti-amyloid-β antibody therapy into clinical practice in Japan, having established a specialized outpatient clinic for this purpose in 2023. She continues to balance clinical practice, research, and advocacy, striving to advance treatment for individuals affected by Alzheimer’s disease.
[S-23-2]アルツハイマー病疾患修飾薬時代における液性バイオマーカーと遺伝学的検査の新たな役割
池内 健 (新潟大学脳研究所 生命科学リソース研究センター)
1991 Graduated from Niigata University School of Medicine
1993 Resident, Neurology, Niigata University Hospital
2000 Ph.D. from Niigata University Graduate School of Medicine
2000 Postdoctral fellow, The University of Chicago
2004 Assistant Professor, Neurology, Niigata University Hospital
2005 Assistant Professor, Brain Research Institute, Niigata University
2007 Program officer, MEXT
2011 Associate Professor, Center for Transdisciplinary Research, Niigata University
2013 Professor, Brain Research Institute, Niigata University (current position)
2020 Director, Medical Genetics Center, Niigata University Medical and Dental Hospital (current position)
1993 Resident, Neurology, Niigata University Hospital
2000 Ph.D. from Niigata University Graduate School of Medicine
2000 Postdoctral fellow, The University of Chicago
2004 Assistant Professor, Neurology, Niigata University Hospital
2005 Assistant Professor, Brain Research Institute, Niigata University
2007 Program officer, MEXT
2011 Associate Professor, Center for Transdisciplinary Research, Niigata University
2013 Professor, Brain Research Institute, Niigata University (current position)
2020 Director, Medical Genetics Center, Niigata University Medical and Dental Hospital (current position)
[S-23-3]Assessing and communicating risk and prognosis in the context of Alzheimer disease
Wiesje van der Flier (Alzheimer center Amsterdam at Amsterdam UMC)
Wiesje van der Flier (1975) is full professor and scientific director of Alzheimer Center Amsterdam at Amsterdam UMC, the Netherlands, where she works since 2004. She studied neuropsychology at the University of Utrecht. In addition, she is clinical epidemiologist. She leads the Amsterdam Dementia Cohort, an ongoing memory-clinic based cohort including over 7000 patients with deep phenotyping (MRI, EEG, CSF biomarkers, and PET) and linked biobank (blood, DNA, CSF). The Amsterdam Dementia Cohort is at the basis of many of the studies performed at Alzheimer center Amsterdam. Van der Flier has been (co)promotor of >40 theses and is currently supervising ~10 PhD projects. Van der Fliers main research areas are looking for the origin of AD, diagnosis&prognosis, and intervention&prevention. Van der Flier leads ABOARD (A Personalized Medicine Approach for Alzheimer’s Disease), a Dutch public-private partnership of than 30 partners (www.aboard-project.nl). She is co-initiator of hersenonderzoek.nl, an online platform to link Dutch citizens interested to contribute to brain research to researchers looking for participants.
[S-23-4]Detecting early Alzheimers disease using digital,fluid, and imaging biomarkers: for the GHABS cohort
Tengfei Guo1,2 (1.Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, 2.Institute of Biomedical Engineering, Shenzhen Graduate School, Peking University)
Dr. Tengfei Guo is an Assistant Professor at the Institute of Neurological and Psychiatric Disorders at Shenzhen Bay Laboratory and Peking University Shenzhen Graduate School. He is primarily devoted to investigating early diagnosis and intervention in Alzheimer’s disease (AD) using multimodal PET and MRI imaging and novel CSF/plasma biomarkers. He initiated the Greater-Bay-Area Healthy Aging Brain Study (GHABS) cohort in 2021, following the standard protocol of the ADNI cohort. More than 1000 older adults have been recruited in GHABS cohort, and completed clinical assessments, fluid biomarkers, MRI imaging, and PET imaging. Based on these data, he has published many research articles in top-tier journals, including Alzheimer’s & Dementia, Molecular Neurodegeneration, Biological Psychiatry, Annals of Neurology, and Neurology as the corresponding author. These contributions have significantly impacted neurodegenerative diseases, particularly in understanding the pathological features, early diagnosis, and clinical trials of AD. He has received funding from the National Science Foundation of China (NSFC) for Excellent Young Scholars, Joint Key Project and General Project, the Guangdong Science Foundation for Distinguished Young Scholars, and the Shenzhen Basic Research Foundation for Excellent Young Scholars.